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10Introduction: Angiogenic and inflammatory factors have
been shown to play an important role in the pathogenesis
of preeclampsia. However, there is little information on
their interaction. The aims of this study were to investigate
the longitudinal pattern of inflammatory markers, such as
interleukin-6 (IL-6) and C-reactive protein (CRP) using a
novel ultra-high sensitive assay method (uhsCRP), and to
explore their relationship with angiogenic factors such as
placental growth factor (PLGF), soluble fms-like tyrosine
kinase-1 (sFlt-1), and vascular endothelial growth factor
(VEGF) in normal pregnancies and pregnancies complicated
by preeclampsia.
Materials and methods: Serum levels of uhsCRP, IL-6,
PLGF, VEGF and s-Flt-1 were longitudinally determined in
16 women with normal, singleton healthy pregnancies at
7–13, 17–22, 27–31 and 37–41 weeks of gestation by
ELISA. uhsCRP was measured using a ultra-high sensitivity
ELISA test. Serum of women with preeclampsia (n¼15)
was available only once, usually in the third trimester of
pregnancy. Women with premature rupture of membranes
(PROM) or infection such as chorioamnionitis were
excluded. Spearman rank correlation, logistic regression,
ROC analysis, ANOVA and Mann–Whitney U-test were
used for statistical purposes.
Results: In normal pregnancies, serum uhsCRP showed a
gestational age-dependent increase (r¼0.40; P<0.001). In
women suffering from preeclampsia, uhsCRP levels were
higher than in gestational age-matched controls
(180104763 versus 3026587 ng/ml; P< 0.001).
Similarly, serum IL-6 levels increased throughout pregnancy
and correlated with uhsCRP in normal pregnancies and in
preeclampsia (n¼64, r¼0.37; P<0.01 and n¼15,
r¼1.00, P<0.0001). uhsCRP levels were positively
correlated with sFlt-1 levels (n¼64, r¼0.34; P< 0.01).
Conclusion: The increases in uhsCRP (and IL-6) serum
levels with advancing gestation indicate a shift towards an
inflammatory state during normal pregnancy. The excessive
rise in uhsCRP and sFlt-1 in preeclampsia indicate that
both may be involved in its pathogenesis. uhsCRP may be
useful as an early marker for preeclampsia and studies
defining the pattern of its rise throughout pregnancies at
risk are urgently needed.
Keywords: angiogenic factors, inflammation,
preeclampsia, pregnancy, ultra-high-sensitivity , C-reactive
protein Copyright © 2019 Wolters Kluwer
12 www.jhypertension.comAbbreviations: ANOVA, analysis of variance; AUC, area
under the curve; CRP, C-reactive protein; CVD,
cardiovascular diseases; hsCRP, high-sensitivity CRP; IL-6,
interleukin-6; IL-8, interleukin-8; NS, not significant; PLGF,
placental growth factor; PROM, premature rupture of
membranes; ROC analysis, receiver-operating characteristic
curve analysis; SD, standard deviation; sFlt-1, soluble fms-
like tyrosine kinase-1; SGA, small for gestational age; TMB,
3,30,5,50-Tetramethylbenzidine; TNF-a, tumour necrosis
factor-alpha; uhsCRP, ultra-high sensitive C-reactive
protein; VEGF, vascular endothelial growth factorINTRODUCTIONP
reeclampsia, a pregnancy-specific disease character-
ized by hypertension and other signs of systemic
endothelial dysfunction, contributes substantially to
perinatal maternal and neonatal morbidity. Moreover, fol-
lowing preeclampsia, both the mother and her child have a
higher risk to suffer from cardiovascular diseases (CVD)
later in life [1–5]. Normal pregnancy shows features of a
mild chronic inflammation [6]. Women with cardiovascular
risk factors are predisposed to pregnancy-associated hyper-
tensive disorders including pre-eclampsia [7,8]. Risk factors
for atherosclerosis (such as hypertension, dyslipidaemia,
overweight, familiar disposition and diabetes) are also
strong predictors for preeclampsia attesting to a similar
pathogenesis [9] and oxidative stress [10]. Higher soluble
fms-like tyrosine kinase-1 (sFlt-1) levels and sFlt-1/placen-
tal growth factor (PLGF) ratios characteristically found in
women with preeclampsia were shown to be also positively
associated with signs of arterial aging during pregnancy and
1-year postpartum [11]. Moreover, endothelial cells play a
pivotal role in the pathogenesis of these two disorders
[12,13]. Indeed, ischemia and oxidative stress has been Health, Inc. All rights reserved.
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uhsCRP in normal pregnancy and preeclampsiaproposed to cause the endothelial injury observed in pre-
eclampsia [14,15] as well as in atherosclerosis [16,17]. Like
other components of the immune system, C-reactive pro-
tein (CRP) might have – in addition to protective – also
potentially harmful effects. A growing body of evidence
suggests that CRP might be implicated in the pathogenesis
of atherosclerosis [13,16,17] and abdominal aortic aneur-
ysms [18] as well as in the tissue damage occurring in acute
myocardial infarction [19–23]. Increased CRP serum levels
have been identified as an independent risk indicator for
cardiovascular events [24].
Serum CRP levels have been shown to be higher in
pregnant than in nonpregnant women [25]. Compared with
normal pregnancies, the serum levels of CRP and of factors
of the innate immune system were even higher in pre-
eclampsia [26]. However, the information on the usefulness
of CRP as a potential marker for preeclampsia is contradic-
tory [25,27–34]. Wolf et al. [30] and Tjoa et al. [31] have
described elevated CRP levels during the first trimester in
women who subsequently develop preeclampsia, intra-
uterine growth restriction or gestational diabetes mellitus,
whereas others did not detect such an association [32,33].
Mechanisms involving angiogenic factors and pro-inflam-
matory cytokines are known to play a key role in the
process of placentation and the development of preeclamp-
sia [35]. Interleukin-6 (IL-6) is one of the strongest inducers
of hepatic CRP production [35,36]. Altered expression pat-
terns of these factors have been shown to be associated
with adverse pregnancy outcome [37,38]. Our group and
others have shown that elevated serum levels of sFlt-1
and the soluble form of endoglin herald preeclampsia
[34,39,40]. However, the interplay and causal relationship
between these factors and CRP has not been examined in
detail. CRP is usually measured using a nephelometric
method, with a detection limit of approximately 2mg/l.
With the advent of more sensitive assays, such as laser
nephelometry, it was possible to measure CRP levels at a
lower level, but still above 0.15 mg/l. To distinguish
between these two detection methods, the latter was
termed ‘high sensitive’ CRP (hsCRP). In contrast to the
‘classical’ CRP, which is more a clinical parameter to evalu-
ate the degree of inflammation because of various stimuli,
hsCRP has become a promising marker for the evaluation of
the cardiovascular risk. Our group has established a novel
CRP detection assay based on an immunoanalytical tech-
nique [41], which allows a substantial increase in sensitivity,
usually bellow 5 pg/ml. To differentiate our ELISA-based
test from the nephelometric ones, we have decided to name
it ultra-high sensitive CRP (uhsCRP, Table 1). Copyright © 2019 Wolters Kluwer 
TABLE 1. Characterization of different CRP assays
‘Classical’ CRP High
Method Nephelometry Laser n
Area of application Clinical (infectious and
inflammatory diseases)
Screen
card
Commercially available Yes Yes
Sensitivity > 2 mg/l 0.15–1
Material Plasma, ascites, pleural effusion,
spinal fluid, and so forth
Plasma
CRP, C-reactive protein.
Journal of HypertensionThe aim of this pilot study was to longitudinally investi-
gate the serum levels of uhsCRP, IL-6, PLGF, vascular
endothelial growth factor (VEGF) and sFlt-1 in normal
pregnancies and, in addition, to compare these data
with those obtained from pregnant women affected by
preeclampsia.
PATIENTS, MATERIALS ANDMETHODS
Sixteen healthy, nonsmoking women with singleton preg-
nancies were prospectively enrolled upon their first pre-
sentation in our service at 7–13 weeks of gestation. Blood
was drawn longitudinally between 7–13, 17–22, 27–31 and
37–41 weeks of gestation. The serum was stored at 808C
after coagulation and centrifugation. None of these women
had premature rupture of membranes or an infectious
condition, such as chorioamnionitis. In addition, 15 women
who were diagnosed with preeclampsia underwent an
antenatal blood collection. Preeclampsia was defined as
hypertension (DBP 90mmHg and/or a systolic pressure
140 mmHg) occurring with proteinuria of at least 300 mg
per 24 h.
CRP was assayed with a self-established, ultra-highly
sensitivity enzyme immunoassay method developed in
our laboratory published elsewhere [41]. Briefly, 96-well
Nunc Maxisorp microtitre plates were coated overnight
with rabbit anti-human CRP [Sigma C3527, 2mg/ml (Sigma,
Dorset, UK) in PBS, 100 ml/well] and the excess sites
blocked with BSA (0.5% w/v in PBS, 250 ml/well). Standards
(CRP, Sigma C4064, at 25–0.39 ng/ml in 1:2 dilution steps)
or samples were added (100 ml/well) in PBS containing
0.5% nonfat milk proteins [Blotto, Pierce Protein Research
Products (ThermoFisher, Rockford, Illinois, USA)], fol-
lowed by an incubation for 2 h at room temperature and
with a shaking speed of 500 rpm. The detection antibody
was rabbit anti-human CRP conjugated with horseradish
peroxidase (HRP, Dako P0227, 1:10 000 in Blotto) in a 1-h
incubation (other parameters unchanged). Washing
between all incubations was with PBS containing Tween-
20 (Sigma, 0.1% v/v, PBST) throughout the procedure.
Ready to use 3,30,5,50-Tetramethylbenzidine (TMB) sub-
strate solution (100 ml, Zymed Inc., San Francisco, Califor-
nia, USA) was added in a timed sequence. After 10–20min
of incubation at room temperature in the dark, the reaction
was stopped by the addition of 100 ml of 2mol/l hydro-
chloric acid and the optical density was determined with a
dual channel microplate reader at 450 nm against a refer-
ence at 590 nm. At midstandard concentration, intra-assay
and inter-assay coefficients of variance were 3.1 and 5.5%,Health, Inc. All rights reserved.
sensitive CRP (hsCRP) Ultra-high sensitive CRP (uhsCRP)
ephelometry ELISA
ing (marker for
iovascular risk evaluation)
Experimental (potential marker for
the prediction of preeclampsia)
No
0 mg/l <5 pg/ml
Plasma
www.jhypertension.com 1013
TABLE 2. Clinical characteristics
Characteristics Preeclampsia (n¼15) Controls (n¼16) Significance, P value
Age (years) 30.10.52 30.50.34 <0.05
Gestational age at delivery (weeks) 320.68 39.90.85 <0.0001
Nulliparous 10 (66.7%) 8 (50%) NS
Preconceptional BMI (kg/m2) 26.20.81 260.78 NS
Cesarean delivery (n, %) 12 (80%) 4 (25%) <0.01
SBP at inclusion (mmHg) 145.312.6 1170.4 <0.0001
DBP at inclusion (mmHg) 94.511.7 74.38.7 <0.0001
Birth weight (g) 1780975 3480419 <.0001
SGA 9 (60%) 2 (12.5%) <0.01
Data are presented as mean SD or n (%). NS, not significant; SGA, small for gestational age (birth weight <10th centile).
Raio et al.respectively. The functional sensitivity of this assay was
below 5pg/ml.
IL-6 was determined with a commercially available
ELISA (Quantikine, R&D Systems, Oxford, England). The
functional sensitivity was 0.2 pg/ml and the serum was
assayed without prior dilution. VEGF was similarly mea-
sured with a Quantikine ELISA kit from R&D Systems and
following the manufacturers’ instructions for serum without
modification. sFlt-1 and PLGF was determined with a micro-
plate ELISA set up in our laboratory with antibodies
obtained from R&D Systems and as previously described
[42].
Data analysis and statistical testing was performed with
GraphPad Prism version 5.0 (GraphPad Software, La Jolla,
California, USA). All data are shown as mean SD. Con-
tinuous variables were compared using the student t-test or
the Mann–Whitney U-test, whereas for the longitudinal
data, ANOVA was used. D’Agostino test was used to check
for normal distribution. Correlations were searched using
Spearman rank test. Statistical significance was defined by a
P value less than 0.05. The study has been approved by the
local ethical committee.
RESULTS
The clinical characteristics of the study population are
presented in Table 2. Serum uhsCRP levels were found
to increase with gestational age in normal, healthy preg-
nancies (r¼ 0.40; P< 0.001, Fig. 1; Spearman rank correla-
tion). When women were stratified in groups ranging from Copyright © 2019 Wolters Kluwer
FIGURE 1 Serum levels of ultra-high sensitive assay method correlate with gesta-
tional age during normal healthy pregnancies (Spearman rank correlation r¼0.35;
P¼0.005).
1014 www.jhypertension.com7 to 13, 17 to 22, 27 to 31 and 37 to 41 weeks of gestation,
uhsCRP serum levels increased from 2647 661 to
15.037 4877 ng/ml at term gestation (P< 0.05, Student’s
t-test). Mean uhsCRP concentrations of women with pre-
eclampsia (n¼ 15) at the time of delivery were higher when
compared with controls (n¼ 16) at term (17960 4591
versus 15037 4877 ng/ml; P¼ 0.67). This finding was fur-
ther enhanced as gestational age at delivery was signifi-
cantly lower in women with preeclampsia (32 0.68
weeks, mean SD) than in the controls (39.9 0.85 weeks;
P< 0.001). Gestational age-matched pairs (1 week of
gestation) of women with preeclampsia and normal preg-
nancy (controls) confirmed the higher uhsCRP levels in
women with preeclampsia (preeclampsia versus controls;
n¼ 7 for both groups; 16960 5161 versus 3416 1268 ng/
ml, respectively; P¼ 0.026, Fig. 2, panel a). Receiver-oper-
ating characteristic curves (ROC) analysis was performed to
assess the test performance for uhsCRP to diagnose pre-
eclampsia. ROC analysis yielded an AUC of 0. 88 [95%
confidence interval (CI) 0.69 to 1; P¼ 0.02; Fig. 2, panel b].
Protein expression of IL-6, a known potent stimulus for
CRP production in various tissues, was analysed in our
samples to investigate a possible impact on uhsCRP protein
expression. IL-6 could be detected in the first trimester only
in four samples [4/16 (25%)] whereas the detection rate
increased to 31.3, 50 and 100% in the second, and third
trimester, and at term gestation, respectively, at a threshold
of 0.2 pg/ml. A positive correlation was found between
the serum concentrations of IL-6 and CRP in healthy preg-
nancies (r¼ 0.37; P< 0.01, Spearman rank correlation).
This correlation was even more pronounced in women
with preeclampsia (r¼ 0.99, P< 0.001, Spearman rank
correlation).
The serum concentrations of the soluble Flt-1 increased
with advancing gestation in normal pregnancies (r¼ 0.56;
P< 0.001, Spearman rank correlation) and was positively
correlated with uhsCRP (r¼ 0.34; P< 0.01, Spearman rank
correlation, Fig. 3). ROC analysis were calculated to assess
test performance regarding the diagnosis of preeclampsia
and yielded an AUC of 0.92 (95% CI 0.87–0.98; P< 0.0001),
and 0.94 (95% CI 0.87–1; P< 0.0001) for sFlt-1, and the sFlt-
1/PLGF-ratio, respectively. As uhsCRP correlates with sFlt-
1, the combination of uhsCRP and sFlt-1 (AUC: 0.92, 95% CI
0.85–0.98) did not substantially change the test perfor-
mance when compared with sFlt-1 alone. No correlation
was found between uhsCRP and both PLGF as well as
VEGF (PLGF: r¼ 0.22; P¼ 0.08; VEGF: r¼0.09; P¼ 0.46,
respectively). Health, Inc. All rights reserved.
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FIGURE 2 (a) Ultra-high sensitive C-reactive protein serum levels were higher in preeclampsia than in gestational age-matched controls (n¼7 for both groups;
169605161 versus 34161268 ng/ml, respectively; P¼0.027, Student’s t-test; presented as box and whisker plots. (b) Receiver operating characteristic curve analysis
for the diagnosis of preeclampsia yielded an area under the curve of 0.88 (95% confidence interval 0.69–1; P¼0.02).
uhsCRP in normal pregnancy and preeclampsiaDISCUSSION
Our data showed that in normal pregnancy, the inflamma-
tory marker uhsCRP increased with advancing gestation,
which went in parallel with an increase in IL-6 serum levels.
Similarly, in our healthy population, sFlt-1 serum levels
increased with gestational age. sFlt-1 is a marker of endo-
thelial activation [43] and enables assessing cardiovascular
risk [44]. In our healthy pregnant population, both sFlt-1
and uhsCRP rose throughout the whole pregnancy, which
underline the inflammatory features of pregnancy per se
and the concept that pregnancy is a state of low-grade
chronic inflammation [6].
CRP is a major acute-phase plasma protein displaying a
rapid and pronounced rise in its serum concentration in
response to infection or tissue injury. A growing body of
experimental and clinical evidence suggests that the pro-
duction of CRP is not restricted to the liver, but that also
cortical tubules as well as glomerular cells of the kidney are
able to produce CRP mainly in nephrectomized renal
allografts with severe acute rejection [45]. It is of particular
interest that Ghezzi et al. [46] were able to show that CRP is
also present in the amniotic fluid at the time when amnio-
centesis for genetic analysis is performed, and elevated Copyright © 2019 Wolters Kluwer 
FIGURE 3 In normal pregnancy ultra-high sensitive C-reactive protein serum con-
centrations correlate with soluble fms-like tyrosine kinase-1 serum levels (n¼64,
r¼0.34; P<0.01, Spearman rank correlation).
Journal of Hypertensionlevels have been associated with adverse pregnancy out-
come, such as preterm delivery as well as preeclampsia.
Higher amniotic fluid CRP concentrations have also been
found in cases with preterm premature rupture of mem-
branes and intra-amniotic infection [47], underscoring its
role as an acute phase reactant against micro-organisms
also within the intra-amniotic cavity. Our group showed
previously that fetal urine contains CRP, which may be an
important source for the amniotic fluid CRP [48]. Indeed,
because of its molecular mass and also absent placental Fc-
receptors, maternal CRP is not able to cross the placental
barrier [41,46]. Other epithelial organs, for example, human
thymic epithelial cells and epithelial cells of the respiratory
tract, are also capable to produce CRP [49,50]. Even neuro-
nal cells seem to synthesize acute phase reactants involved
in the pathogenesis of neurodegenerative diseases [51]. It is,
therefore, possible that the acute phase response not
merely represents a systemic inflammatory pathway, but
is probably also part of the local inflammatory response.
Our group has demonstrated that the placenta is another
important site of CRP production [41]. The majority of the
synthesized CRP is released by the placenta into the mater-
nal circulation. This may explain the increasing CRP con-
centration found in the longitudinal assessment of our
population of healthy pregnancies.
Endothelial activation is an integral component of the
inflammatory response. In relation to local injury, activated
endothelium targets inflammatory leukocytes by anchoring
them to the vessel wall where they are stimulated to
transmigrate into extravascular tissues. The relationship is
by two ways. Activated leukocytes, especially granulocytes,
can stimulate the endothelium [37]. Redman et al. [52] and
Sacks et al. [53] were able to demonstrate that in response to
preeclampsia, a generalized systemic maternal inflamma-
tory response that not only affects circulating leukocytes
but also monocytes and lymphocytes, is present. Moreover,
some investigators found significantly increased circulating
levels of pro-inflammatory cytokines, such as tumour
necrosis factor-alpha (TNF-a), interleukin (IL)-6 and IL-8
[35,36]. The observation that this inflammatory state is
already present to a milder extent in normal pregnanciesHealth, Inc. All rights reserved.
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Raio et al.led to the hypothesis that preeclampsia develops when the
systemic inflammatory process, common to all women in
the second half of gestation as observed in our study, causes
maternal regulatory mechanisms to decompensate [52]. The
same pro-inflammatory cytokines are strong stimulators
of the hepatic (and other) CRP production and, together
with the CRP secreted by the placenta, may explain
the gestational age-dependent increase of CRP in healthy
pregnancies. Similarly, the higher CRP values found in our
preeclampsia group may reflect the increased inflammatory
burst observed in these women.
There seems to be a complex and still poorly understood
action and interaction between inflammatory and angio-
genic mechanisms during normal pregnancy. This system is
altered in women who develop preeclampsia, and in addi-
tion to the angiogenic parameters, it seems that CRP might
play an interesting role in this context. However, CRP
correlated only with sFlt-1, which is also associated with
the maternal inflammatory state during pregnancy [6] and in
particular during preeclampsia [26].
It is noteworthy that hsCRP is one of the most frequently
used markers for cardiovascular risk assessment. HsCRP is a
key laboratory tool in the prognosis and prediction of
cardiovascular disease [54,55]. It is of particular interest that
women after preeclampsia are at increased risk for cardio-
vascular diseases later in life [3,56,57] and higher CRP levels
are found even several decades following eclamptic preg-
nancy [58]. This finding might – at least partly – explain the
increased risk for CVD in women with a history of hyper-
tensive pregnancy disorders [1–5]. Moreover, hsCRP has
also been associated with early pregnancy loss and low-
dose aspirin administered to women with increased inflam-
mation defined by higher hsCRP levels, lowered hsCRP
concentrations throughout pregnancy and increased live
birth rates [59].
Our method presented here is the determination of
uhsCRP using a totally different approach (ELISA) when
compared with CRP, which is based on the nephelometric
detection of agglutinated CRP and hence requiring a mini-
mum concentration of the analyte, which limits the sensi-
tivity of the assay. Laser nephelometry is used for the
measurement of hsCRP, which increases the sensitivity
by a factor of around 10 but did not change the principle
of the assay. Our uhsCRP protocol is based on an antigen–
antibody interaction, which, by nature, is much stronger,
and thus increases the overall sensitivity of the assay. The
limit of detection of hsCRP is commonly within 0.15–
10mg/l. Our ELISA-based immunoassay method is able
to detect uhsCRP at a significantly lower concentration than
the commercially available hsCRP tests (Table 1). Indeed,
we are dealing with CRP values in the range of picogram
per millilitres. This, together with the different specificities
of the polyclonal antibodies used in our assay, may also
explain the discordant reports about the utility of CRP
assessment during pregnancy reported in the literature to
date [25,27–34].
In conclusion, our small pilot study has shown that the
high detection rate of the uhsCRP test allows assessing the
degree of the physiologic maternal systemic inflammatory
response to pregnancy. Our data demonstrate an associa-
tion between the innate immune system and markers of Copyright © 2019 Wolters Kluwer
1016 www.jhypertension.cominflammation in normal pregnancies and, in particular, in
those complicated by preeclampsia. Our findings of sub-
stantially increased pro-inflammatory and anti-angiogenic
markers in preeclampsia support the hypothesis that CRP
and sFlt-1 play a central role in the pathogenesis of pre-
eclampsia. Hopefully these biochemical markers may be
used as predictive tools and targets for therapies, which will
attenuate endothelial cell dysfunction in preeclampsia and
other endothelium-related diseases. Future studies will
elucidate whether maternal serum uhsCRP measurements
using immunoanalytical methods with functional sensitivi-
ties within nanogram to picogram ranges, as the one
presented in this study, may be of value in early pregnancy
to identify a high-risk population for subsequent hyperten-
sive complications and to detect those women that are at
increased risk for cardiovascular complications later in life.
Larger prospective studies are eagerly needed to confirm
our preliminary results.
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